Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

5.030 -0.030 (-0.59%)
Streaming Delayed Price Updated: 9:47 AM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amneal Pharmaceuticals Inc

< Previous 1 2 3 Next >
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Virtually Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Third Quarter 2021 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Third Quarter 2021 Results on November 3, 2021
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Second Quarter 2021 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives Approval for Generic TobraDex®
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Second Quarter 2021 Results on August 9, 2021
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Virtually Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports First Quarter 2021 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2021 Results on May 7, 2021
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.